Merck’s Positive Winrevair Data Expected To Drive PAH Market Growth

 
• By Alaric DeArment
  
Pulmonary hypertension is a cardiovascular condition characterized by high blood pressure in the pulmonary arteries 3D rendering
Merck announced data from the Phase III HYPERION trial of Winrevair in patients with PAH earlier after diagnosis. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D